A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q)

Cancer type: Leukemia

Phase: II

Principal Investigator: Noergaard Jan M.

Country: DK

Keywords: Denmark, Aarhus

Status: Inclusion completed

Link to